Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.36 +2.1%	$4.24	$1.14 ▼ $7.20	$321.06M	0.76	1.21 million shs	830,529 shs
ENTA Enanta Pharmaceuticals	$6.86 +5.7%	$7.37	$4.09 ▼ $13.43	$146.67M	0.88	285,699 shs	225,273 shs
GLSI Greenwich LifeSciences	$12.35 -1.1%	$10.35	$8.06 ▼ $16.50	$165.12M	1.65	58,689 shs	68,359 shs
VACC Vaccitech	$1.14 -14.9%	$1.57	$1.64 ▼ $5.10	$43.94M	-0.4	244,643 shs	109,183 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-0.19%	+3.35%	+12.90%	+152.40%	+2.94%
ENTA Enanta Pharmaceuticals	-5.94%	-8.59%	-1.07%	+24.09%	-48.41%
GLSI Greenwich LifeSciences	+2.55%	+4.61%	+15.22%	+28.90%	-7.62%
VACC Vaccitech	0.00%	+3.88%	+34.00%	+44.09%	-0.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.1062 of 5 stars	3.5	1.0	0.0	0.0	3.4	0.8	0.6
ENTA Enanta Pharmaceuticals	3.7145 of 5 stars	3.5	0.0	0.0	4.7	2.6	2.5	0.0
GLSI Greenwich LifeSciences	1.8208 of 5 stars	3.5	1.0	0.0	0.0	2.6	1.7	0.0
VACC Vaccitech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	77.24% Upside
ENTA Enanta Pharmaceuticals	3.00	Buy	$21.67	215.84% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	215.79% Upside
VACC Vaccitech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VACC, ALDX, GLSI, and ENTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$24.00 ➝ $25.00
7/28/2025	ENTA Enanta Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
ENTA Enanta Pharmaceuticals	$67.64M	2.17	N/A	N/A	$6.08 per share	1.13
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
VACC Vaccitech	$13.42M	3.27	$0.06 per share	19.30	$6.52 per share	0.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	N/A
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	N/A
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/13/2025 (Estimated)
VACC Vaccitech	$5.34M	-$1.43	N/A	N/A	N/A	-409.18%	-23.41%	-20.85%	N/A

Latest VACC, ALDX, GLSI, and ENTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	GLSI Greenwich LifeSciences	-$0.24	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.25	-$0.85	+$0.40	-$0.85	$16.21 million	$18.31 million
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
VACC Vaccitech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
GLSI Greenwich LifeSciences	N/A	1.91	1.91
VACC Vaccitech	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
ENTA Enanta Pharmaceuticals	94.99%
GLSI Greenwich LifeSciences	4.16%
VACC Vaccitech	26.13%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	8.50%
ENTA Enanta Pharmaceuticals	13.89%
GLSI Greenwich LifeSciences	51.67%
VACC Vaccitech	6.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.81 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
VACC Vaccitech	33	38.55 million	36.23 million	Not Optionable

VACC, ALDX, GLSI, and ENTA Headlines

Recent News About These Companies

VTP-500 by Barinthus Biotherapeutics for Middle East Respiratory Syndrome (MERS): Likelihood of Approval

December 31, 2024 | pharmaceutical-technology.comP

Real-World Data on the RSV Vaccine for Older Adults

November 12, 2024 | msn.com

10 Startups Founded Out Of Oxford University

November 5, 2024 | techround.co.ukT

Ten things to know about new R21 malaria vaccine Nigeria received

October 18, 2024 | premiumtimesng.comP

Nigeria: Ten Things to Know About New R21 Malaria Vaccine Nigeria Received

October 18, 2024 | allafrica.com

Barinthus Bio completes enrolment in hepatitis B and prostate cancer vaccine trials

October 2, 2024 | finance.yahoo.com

Buy Rating Affirmed on Barinthus Biotherapeutics Amid Promising Clinical Trials and Therapeutic Advances

October 1, 2024 | markets.businessinsider.com

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

October 1, 2024 | markets.businessinsider.com

Strong Buy Rating for Barinthus Biotherapeutics Amid Promising Trials in Celiac and Hepatitis B Therapies

September 26, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical Advancements

August 12, 2024 | markets.businessinsider.com

BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024

August 9, 2024 | markets.businessinsider.com

Giving RSV and Flu Vaccines Together Led to Adequate Immune Responses

August 7, 2024 | medpagetoday.comM

How real are the threats to the US dollar?

July 31, 2024 | uk.finance.yahoo.com

Zoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market's Growth

July 29, 2024 | finance.yahoo.com

Google invests in UK vaccine pioneer Vaccitech

July 26, 2024 | pharmaphorum.comP

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

May 22, 2024 | markets.businessinsider.com

Buy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical Trials

May 17, 2024 | markets.businessinsider.com

Real reasons Nigeria still missing out on malaria vaccine rollout

May 11, 2024 | premiumtimesng.comP

Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout

May 3, 2024 | fiercebiotech.comF

News - Leon Hooftman

May 1, 2024 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

VACC, ALDX, GLSI, and ENTA Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.36 +0.11 (+2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$5.39 +0.03 (+0.56%)

As of 06:57 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Enanta Pharmaceuticals NASDAQ:ENTA

$6.86 +0.37 (+5.70%)

Closing price 04:00 PM Eastern

Extended Trading

$6.86 +0.00 (+0.07%)

As of 04:10 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Greenwich LifeSciences NASDAQ:GLSI

$12.35 -0.14 (-1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$12.52 +0.17 (+1.41%)

As of 04:22 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Vaccitech NASDAQ:VACC

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time